Expected R&D *milestones* in 2022

		H1 2022	*H2 2022*	*Status as of Q2*
Dupixent®	EoE	U.S./EU regulatory submissions		Approved **U.S./**Submitted **EU**
	PN	U.S./EU regulatory submissions		Submitted **U.S./EU**
	CSU	Pivotal trial readout (Study B)		Negative readout, program continues
	CInDU		Pivotal trial readout	Now expected in H1 2023
Oncology	amcenestrant 2/3L mBC	Pivotal trial readout		Negative readout (AMEERA-3)
	SAR'245		Phase 3 decision	
	Sarclisa® (1L MM)		Pivotal trial readout (IMROZ)	
	Libtayo® (1L NSCLC CT combo)		U.S. regulatory decision	
Rare Blood Disorders	efanesoctocog alfa (HemA)	Pivotal trial readout	U.S. submission (mid-year)	**Positive** readout
	sutimlimab (CAD)	US regulatory decision		Approved
Rare Diseases	olipudase alfa (ASMD)	JP regulatory decision (SAKIGAKE)	U.S. regulatory decision	Approved **JP/EU**
Vaccines	nirsevimab (RSV)	EU submission	U.S. submission	Submitted **EU**
	RSV Toddler		Pivotal trial decision	
	COVID-19 recombinant	U.S./EU regulatory submissions		Submitted **EU**

As of June 30, 2022, barring unforeseen events. For abbreviations see slide 56.